Nurix appoints Edward C. Saltzman to board of directors

Nurix Therapeutics, Inc.

Appointed effective Sept 12, 2022 as Class II director with term through 2025 annual meeting.
Received initial option for 50,000 shares vesting over 3 years; annual option of 25,000 shares.
Will serve on Compensation Committee and Development Advisory Committee.
Saltzman has over 30 years biopharma strategy experience, currently Head of Biotech Strategy at Lumanity.
Founder of Defined Health, sold to Cello Health; brings strategic development expertise.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Edward C. Saltzman

director

NRIX · Nurix Therapeutics, Inc.

Effective: 2022-09-12
Filed: September 14, 2022, 7:59 PM ET

On September 12, 2022, the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Edward C. Saltzman to serve as a director of the Company and as a member of the Compensation Committee of the Board (the “Compensation Committee”) and the Development Advisory Committee of the Board (the “Development Advisory Committee”), effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Edward C. Saltzman was appointed as director at Nurix Therapeutics, Inc..

Action: appointed
Role: director

Exact text from the filing

On September 12, 2022, the board of directors (the “Board”) of Nurix Therapeutics, Inc. (the “Company”), following a recommendation from the Nominating and Corporate Governance Committee of the Board, appointed Edward C. Saltzman to serve as a director of the Company and as a member of the Compensation Committee of the Board (the “Compensation Committee”) and the Development Advisory Committee of the Board (the “Development Advisory Committee”), effective immediately.

View on SEC.gov

Nurix Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-244711

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.